<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DF930BA1-5D36-4AE0-AE42-08B4B2D37BFA"><gtr:id>DF930BA1-5D36-4AE0-AE42-08B4B2D37BFA</gtr:id><gtr:name>Pasteur Merieux Serums</gtr:name><gtr:address><gtr:line1>Mallards Reach</gtr:line1><gtr:line2>Bridge Avenue</gtr:line2><gtr:postCode>SL6 1QP</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/81FFBBDE-DDA9-47C3-912B-A6BD09AE4C46"><gtr:id>81FFBBDE-DDA9-47C3-912B-A6BD09AE4C46</gtr:id><gtr:name>University of Eastern Piedmont</gtr:name><gtr:address><gtr:line1>Amedeo Avogadro</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D6C3234E-5048-4AA0-A116-0CAC51569B2D"><gtr:id>D6C3234E-5048-4AA0-A116-0CAC51569B2D</gtr:id><gtr:name>University of Queensland</gtr:name><gtr:address><gtr:line1>University of Queensland</gtr:line1><gtr:line4>Brisbane</gtr:line4><gtr:line5>Queensland 4972</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0AEFDD04-383A-4977-9F05-440376448760"><gtr:id>0AEFDD04-383A-4977-9F05-440376448760</gtr:id><gtr:name>International Centre for Genetic Engineering and Biotechnology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0678FAD7-6E5E-4BC3-9B8C-76FA3057B994"><gtr:id>0678FAD7-6E5E-4BC3-9B8C-76FA3057B994</gtr:id><gtr:name>Drexel University</gtr:name><gtr:address><gtr:line1>Drexel University</gtr:line1><gtr:line2>Disque Hall 816</gtr:line2><gtr:line3>3141 Chestnut Street</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/750AAF87-60DC-4D95-B294-32C8AE85B202"><gtr:id>750AAF87-60DC-4D95-B294-32C8AE85B202</gtr:id><gtr:name>DDL Diagnostic Laboratory</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DF930BA1-5D36-4AE0-AE42-08B4B2D37BFA"><gtr:id>DF930BA1-5D36-4AE0-AE42-08B4B2D37BFA</gtr:id><gtr:name>Pasteur Merieux Serums</gtr:name><gtr:address><gtr:line1>Mallards Reach</gtr:line1><gtr:line2>Bridge Avenue</gtr:line2><gtr:postCode>SL6 1QP</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/81FFBBDE-DDA9-47C3-912B-A6BD09AE4C46"><gtr:id>81FFBBDE-DDA9-47C3-912B-A6BD09AE4C46</gtr:id><gtr:name>University of Eastern Piedmont</gtr:name><gtr:address><gtr:line1>Amedeo Avogadro</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D6C3234E-5048-4AA0-A116-0CAC51569B2D"><gtr:id>D6C3234E-5048-4AA0-A116-0CAC51569B2D</gtr:id><gtr:name>University of Queensland</gtr:name><gtr:address><gtr:line1>University of Queensland</gtr:line1><gtr:line4>Brisbane</gtr:line4><gtr:line5>Queensland 4972</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0AEFDD04-383A-4977-9F05-440376448760"><gtr:id>0AEFDD04-383A-4977-9F05-440376448760</gtr:id><gtr:name>International Centre for Genetic Engineering and Biotechnology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0678FAD7-6E5E-4BC3-9B8C-76FA3057B994"><gtr:id>0678FAD7-6E5E-4BC3-9B8C-76FA3057B994</gtr:id><gtr:name>Drexel University</gtr:name><gtr:address><gtr:line1>Drexel University</gtr:line1><gtr:line2>Disque Hall 816</gtr:line2><gtr:line3>3141 Chestnut Street</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/750AAF87-60DC-4D95-B294-32C8AE85B202"><gtr:id>750AAF87-60DC-4D95-B294-32C8AE85B202</gtr:id><gtr:name>DDL Diagnostic Laboratory</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E7D29686-C3D9-4B74-BA57-EE760EAC9E08"><gtr:id>E7D29686-C3D9-4B74-BA57-EE760EAC9E08</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Doorbar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117584278"><gtr:id>63A85E40-1CF9-440D-B9ED-60AACCC1CCBB</gtr:id><gtr:title>Molecular Biology of Human Papillomavirus Infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117584278</gtr:grantReference><gtr:abstractText>There are many different types of human papillomavirus (HPV). They all infect epithelial tissue such as the skin, but some cause common warts while others cause genital warts. Certain HPV types are classified as high-risk, because they cause cervical lesions (flat warts) that can in some women progress to cervical cancer. These high-risk HPV types are responsible for virtually all cases of cervical cancer worldwide. Cervical cancer is the second most common cancer amongst women with about half a million cases occurring each year.||Our aim is to understand the molecular basis of disease, and to identify the events that deregulate the normal virus life cycle. This work follows a number of different paths. One aspect establishes the function of the viral proteins and aims to understand how they work together to produce disease. As part of this work we are using model systems of the skin to culture the virus in the laboratory. Another aspect of the work is looking at how the virus changes cellular gene expression, and what causes a wart like infection of the cervix to progress to neoplasia. This work has potential for improved cervical screening and better strategies for vaccination and therapy.</gtr:abstractText><gtr:technicalSummary>Human papillomaviruses cause a range of epithelial lesions including benign genital warts and cervical intraepithelial neoplasia (CIN). Both are of significant medical importance, with certain HPV types (known as high-risk types) being responsible for the development of cervical cancer in women who cannot resolve their infection. Our focus is on the Alpha papillomaviruses that cause genital warts and cervical disease, but we are also interested in the four other evolutionary groups of papillomavirus including the Beta HPV types that may be involved in the development of skin cancers and which can be a problem in immunosuppressed individuals. The work of the lab falls into three broad areas, which are described below. 1. Molecular Analysis of Human Papillomavirus Protein Function. This has concentrated on the E4 protein, which we have shown previously to bind keratin and certain cyclin dependent kinases to induce G2 arrest. Our current studies centre around the finding that E4 can assemble into amyloid fibrils, and that its function is modulated by phosphorylation and proteolytic cleavage. The finding that high-risk E4 contributes to viral genome amplification in model systems has prompted us to study the importance of the association between the HPV16 E4 protein and the viral replication factor E2. 2. Role of Viral Gene Products During Infection using Model Systems. To understand how viral protein function is modulated during infection, we have used raft culture and gene knock-outs. This system is also allowing us to examine the mechanisms that regulate normal HPV gene expression and to establish what factors are involved in the progression to high-grade neoplasia and cancer. Raft culture provides an important system for the validation of the results generated from the molecular studies described above. Where involvement of the immune system needs to be considered, we are using the rabbit oral papillomavirus model. This is particularly valuable in understanding the basis of viral latency. 3. Natural History of Infection in Humans. The third part of the work examines gene expression patterns in clinical tissue, as this is the gold standard that the molecular studies and the use of model systems must explain. Our goal is to understand the intermediate states that connect productive infection to cervical cancer, and to establish what factors may contribute to life cycle de-regulation in infected cervix. An important off-shoot of this work is the development of biomarker approaches for the evaluation of cervical neoplasia. The biomarker work is of relevance to industry, and we have close contacts with a number of diagnostic and vaccine companies and are currently involved in collaborative studies aimed at improving cervical diagnosis. In addition to the above, we have recently used intrabodies to inhibit HPV protein function in cells. This has contributed to our knowledge of which viral proteins are important for maintenance of the disease state.</gtr:technicalSummary><gtr:fund><gtr:end>2013-10-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>7668234</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK-Collaborative Research Grant 2007-2008</gtr:description><gtr:id>6CFB33CB-89FB-4970-A631-FCC01422A155</gtr:id><gtr:impact>Two manuscripts is now in the final stage of preparation and are planned for publication in 2010. Copies can be provided if necessary.</gtr:impact><gtr:outcomeId>6C1F98EC708-1</gtr:outcomeId><gtr:partnerContribution>Regular (monthly) meetings with collaborators on this project at Glaxo Smith Kline, Rixensart, and at Delft Diagnostic Laboratories, Holland. These meetings comprise scientific strategy discussions. Insight from scientists with clinical and diagnostic backgrounds are passed to us which enhances our understanding and the general quality of our work.</gtr:partnerContribution><gtr:piContribution>We head the Papillomavirus life-cycle side of the studies and are concerned with establishing new reagents that allow the HPV life-cycle to be better understood and to provide insight into HPV biology. We have done a considerable amount of analysis on GSK-collected clinical material that has provided valuable data for GSK and a significan new body of information that helps us to better understand how HPVs work. Two GSK-funded members of the lab are currently in place at NIMR and are supervised by myself.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi Pasteur MSD</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SPMSD Lyon</gtr:description><gtr:id>D31E7293-44A9-440A-9FC7-5425C1219E48</gtr:id><gtr:impact>manuscript in viral latency published. Review in press</gtr:impact><gtr:outcomeId>KqWm3LnHLZ9-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input. Access to new research area</gtr:partnerContribution><gtr:piContribution>project design and implementation</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Protein Engineering</gtr:department><gtr:description>Protein Engineering/Intrabodies</gtr:description><gtr:id>7B6CD55A-5CE3-4AC2-A6A3-D4050652ABF3</gtr:id><gtr:impact>16324714; 19. Griffin, H., R. Elston, D. Jackson, K. Ansell, M. Coleman, G. Winter, and J. Doorbar. 2006. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol 355:360-78.</gtr:impact><gtr:outcomeId>B7F66325A2F-1</gtr:outcomeId><gtr:partnerContribution>Joint research publication. Scientific discussion and advice.</gtr:partnerContribution><gtr:piContribution>Driven research into the use of intrabodies in HPV therapy. This has now been followed up by other groups.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Queensland</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>University of Queensland Diamantina Institute (UQDI)</gtr:department><gtr:description>University of Queensland/L1 expression in G2</gtr:description><gtr:id>7424A601-2E7F-4D14-B40F-B92C55278410</gtr:id><gtr:impact>Research manuscript just accepted for publication in Virology. 5. Ding, J., Doorbar, J., Li,B., Zhou, F., Gu, W., Zhao, L., Saunders, N.A., Frazer, I.H. and Zhao, K-N. Expression of papillomavirus L1 proteins is favoured in G2/M-like cells in differentiating keratinocytes. Virology (2010) in press</gtr:impact><gtr:outcomeId>328AE626F97-1</gtr:outcomeId><gtr:partnerContribution>Research collaboration involving the interchange of ideas and the hosting of visitors from the Diamantina Institute at NIMR.</gtr:partnerContribution><gtr:piContribution>We have provided scientific input and carried out experiments at NIMR to complete aspects of the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Centre for Genetic Engineering and Biotechnology</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>ICGEB Trieste/Oncogene expression</gtr:description><gtr:id>BC3C7D5D-B4A1-4764-A8A8-88794604AEA6</gtr:id><gtr:impact>19421149; 10. Gammoh, N., Isaacson, E., Doorbar, J and Banks, L. Inhibition of HPV16 E7 Oncogene Expression by E2. Oncogene (2009) 28, 2299-2304</gtr:impact><gtr:outcomeId>B1C5BD6E5A5-1</gtr:outcomeId><gtr:partnerContribution>Discussion of scientific data and ideas. Acquisition of specific research skills.</gtr:partnerContribution><gtr:piContribution>Hosting visitors from ICGEB. Providing advice and training in specific methods. Development of ideas through discussion.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>DDL Diagnostic Laboratory</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>HPV Infection and Pathology</gtr:description><gtr:id>A96D0678-8224-4E37-B8EF-1805B324B1C5</gtr:id><gtr:impact>J Pathol. 2011 Nov 30. doi: 10.1002/path.3970. [Epub ahead of print]</gtr:impact><gtr:outcomeId>pHcbUYL8cdg-1</gtr:outcomeId><gtr:partnerContribution>Intellectual discussion. Access to clinical community</gtr:partnerContribution><gtr:piContribution>Initiation and development of laser capture methods as part of external project</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Otago</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Department of Microbiology &amp; Immunology</gtr:department><gtr:description>University of Otago/Immunology of Papillomaviruses</gtr:description><gtr:id>E0623726-C238-44FE-AAD5-2963C02DC05F</gtr:id><gtr:impact>19759549 ; 7. Leong, C-M, Doorbar, J., Yoon, H-S, Hibma, M.H. Analysis of Langerhans cells in epidermis infected with human papillomavirus types from four genera. J. Invest. Dermatol. (2009) Sept 17 (Epub ahead of print)</gtr:impact><gtr:outcomeId>06F74A9C973-1</gtr:outcomeId><gtr:partnerContribution>This is a research collaboration in which researchers at the University of Otago (lead by Dr. Merilyn Hibma)contributed to a joint research project. This lead to a publication in 2009.</gtr:partnerContribution><gtr:piContribution>Hosted scientists from University of Otago (Leong,C-M and Hibma,M.) who have worked in our lab. Through discussion, we have developed the project with them and provided specific training in the use of approaches. We have provided archived clinical material and helped with HPV typing and immunostaining.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Eastern Piedmont</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Dermatology Clinic</gtr:department><gtr:description>Beta HPV Disease</gtr:description><gtr:id>1CF2CBB8-7C69-4E4A-9959-90FDCEF656C2</gtr:id><gtr:impact>Manuscript for Virology Published</gtr:impact><gtr:outcomeId>A2vMJJGc8Vd-1</gtr:outcomeId><gtr:partnerContribution>Intellectual Discussion</gtr:partnerContribution><gtr:piContribution>Experimental Design, Development of methodologies, analysis of clinical material</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Drexel University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>University of Philadelphia/HPV11 life cycle</gtr:description><gtr:id>41C3B645-5FFD-4040-962E-2617C57A8E93</gtr:id><gtr:impact>16687161; 17. Fang, L., L.R. Budgeon, J Doorbar, E.R. Briggs and MK Howett. 2006. The human papillomavirus type 11 E1^E4 protein is not essential for viral genome amplification. Virology 351:271-279</gtr:impact><gtr:outcomeId>EED511836E9-1</gtr:outcomeId><gtr:partnerContribution>Research discussions.</gtr:partnerContribution><gtr:piContribution>Carrying out specific scientific experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK-Collaborative Research Grant 2008-2009</gtr:description><gtr:id>D3F9DB9E-C2B5-4BCA-9B7E-0BA65FAFC247</gtr:id><gtr:impact>Two manuscripts is now in the final stage of preparation and are planned for publication in 2010. Copies can be provided if necessary.</gtr:impact><gtr:outcomeId>30BEB32EE57-1</gtr:outcomeId><gtr:partnerContribution>Regular (monthly) meetings with collaborators on this project at Glaxo Smith Kline, Rixensart, and at Delft Diagnostic Laboratories, Holland. These meetings comprise scientific strategy discussions. Insight from scientists with clinical and diagnostic backgrounds are passed to us which enhances our understanding and the general quality of our work.</gtr:partnerContribution><gtr:piContribution>We head the Papillomavirus life-cycle side of the studies and are concerned with establishing new reagents that allow the HPV life-cycle to be better understood and to provide insight into HPV biology. We have done a considerable amount of analysis on GSK-collected clinical material that has provided valuable data for GSK and a significan new body of information that helps us to better understand how HPVs work. Two GSK-funded members of the lab are currently in place at NIMR and are supervised by myself.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi Pasteur MSD</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Gynaecology</gtr:department><gtr:description>SPMSD Denmark</gtr:description><gtr:id>544B241B-F453-495F-A5DC-408F0A9130C9</gtr:id><gtr:impact>presentations at meetings. Eventually a manuscript.</gtr:impact><gtr:outcomeId>aeUqCo9hzMp-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input. Cross discipline research</gtr:partnerContribution><gtr:piContribution>technology input and knowledge</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Beta HPV + Skin Disease</gtr:description><gtr:id>6D328BF7-1BF0-4DB8-8E63-AAE101096BE0</gtr:id><gtr:impact>expected publication</gtr:impact><gtr:outcomeId>nWPumsmP3Wr-1</gtr:outcomeId><gtr:partnerContribution>collection of clinical material</gtr:partnerContribution><gtr:piContribution>analysis of Beta HPV infections in the skin using specific reagent.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Health Professional Education</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F5C4A7CB-DC1D-467C-9C7B-5FA5E12DA8DB</gtr:id><gtr:impact>Dissemination of knowledge to individuals who are interested in learning more about HPV in light of the new HPV vaccine

Valuable collaboration with clinical scientists set up.</gtr:impact><gtr:outcomeId>A48128D5E41</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Presentations to Health Care Professionals, Medical Professionals and Researchers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D990F173-67AC-40F0-8DF4-A9FE05E00DFB</gtr:id><gtr:impact>1. January 31st 2007 HPV Infection and Human Disease. National Institute for Medical Research, London, UK. (Institute Seminar Series (Research Seminar))

2. February 20th 2007 E4 Function During HPV Infection. University of Sussex, Falmer, Brighton, UK. (Invited Research Seminar)

3. March 23rd 2007 The Papillomavirus Life Cycle. GlaxoSmithKline Biologicals, Rixensart, Belgium. (Invited Research Seminar)

4. March 28th 2007 Papillomavirus Replication: From Entry through to Exit. 160th meeting of the Society for General Microbiology, University of Manchester (Plenary Lecture)

5. April 26th 2007 The Biology of HPV Infection and Cervical Disease. The VI Conference of The Israeli Society of Gynecologic Oncology, Herzeliya, Israel. (Plenary Lecture)

6. May 9th 2007, September 24th 2007, October 17th 2007, November 26th 2007 HPV : the missing link. Preventing cervical cancer: a realistic goal?
One-day conference for Clinical Scientists and Health Care professionals organised by The Royal Society of Medicine to coincide with the introduction of the HPV vaccine in the UK. St Anne's College, Oxford, UK., University of Sussex, Brighton, UK., John Innes Centre, Norwich, UK., University of Birmingham, UK. (Invited Lectures)

7. May 25th 2007 Advances in the Molecular Biology of HPV Infection and its Application in Cervical Cancer Early Detection. International HPV Clinical Training and Scientific Workshop, University of Antioquia, Medellin, Columbia. (Plenary Lecture, Session Chair)

8. June 5th 2007 Papillomavirus Gene Expression and Protein Function. International Centre for Genetic Engineering and Biotechnology, Trieste, Italy. (Invited Research Seminar)

9. July 6th 2007 Molecular Basis of HPV-associated Disease. 31st British International Congress of Obstetrics &amp;amp; Gynaecology, ExCel Docklands, London (Invited Lecture)

10. July 10th 2007 HPV-Associated Disease and Intrabody Therapy. GlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom, (Invited Research Seminar)

11. October 9th 2007 Understanding the Biology of HPV Infection. NIBSC, Potters Bar, United Kingdom. (Invited Research Seminar)

12. October 20th 2007 Biology of HPV Infection and Persistence. Symposium on HPV infection and Associated Disease. Limassol, Cyprus. (Invited Lecture)

13. November 3rd 2007 The Human Papillomavirus Life Cycle. Clinical Workshop, 24th IPV Meeting, Beijing, China. (Invited Lecture, Session Chair)

14. December 7th 2007 Molecular Basis of HPV-Associated Disease. European Vaccine Symposium, Brussels, Belgium. (Invited Lecture)

15. February 21-22nd 2008 The Papillomavirus Life Cycle and Vaccine Effects. SPMSD European Expert Panel Meeting, Paris, France. (Invited Lecture)

16. March 5-8, 2008 Papillomavirus Infection and Disease. German Society of Virology Annual Meeting, Heidelberg, Germany. (Plenary Lecture)

17. May 2nd 2008 Understanding the molecular biology of human papillomavirus infection and cervical neoplasia. Griffith University, Gold Coast, Australia. (Invited Research Seminar)

18. May 5th 2008 Understanding the Papillomavirus Life Cycle in Infected Epithelium. University of Otago, Dunedin, New Zealand. (Invited Research Seminar)

19. May 6th 2008 Current Problems in Papillomavirus Research. Diamantina Institute, University of Queensland, Queensland, Australia. (Invited Research Seminar)

20. May 13th 2008 The Biology of Papillomavirus Infection. European Society of Pediatric Infectious Diseases Annual Meeting, Graz, Austria. (Invited Lecture)

21. May 15th 2008, June 5th 2008 Understanding HPV Infection and Vaccination. HPV Immunization Workshop. Royal Horticultural Halls, London, Vermont Hotel, Newcastle-on-Tyne (Invited Lectures)

22. May 19th 2008 The HPV Life Cycle; From Infection to Cervical Cancer. SPMSD European Expert Meeting, Sheraton Hotel, Frankfurt, Germany (Invited Lecture)

23. June 13th 2008 Molecular Understanding of Papillomaviruses and Neoplasia. Irish Colposcopy Training Course, Coombe Womens Hospital, Dublin, Ireland. (Invited Lecture)

24. September 18th 2008 Human Papillomavirus Infection and Vaccination, European Association of Dermatology and Venerology, Palais de Congress, Paris (Invited Lecture)

25. October 23rd 2008 Papillomavirus Life Cycle Events During Productive and Abortive Infection and During Viral Latency. 5th International HPV and Skin Cancer Conference, Heidelberg, Germany. (Invited Lecture)

26. November 27th 2008 The Papilomavirus Life Cycle and Human Disease. Institut Catala d'Oncologica, Barcelona, Spain. (Invited Lecture) 

27. January 28th 2009 Papillomavirus Regulation and Deregulation. National Cancer Institute, Bethesda, Maryland, USA (Invited Research Seminar)

28. March 16th 2009 Papillomaviruses and Neoplastic Progression, ICGEB, Trieste, Italy (Invited Research Seminar)

29. May 7th 2009 The Biology of HPV and Disease, British Society for Colposcopy and Cervical Pathology (Annual Scientific Meeting), Dublin, Ireland. (Plenary Lecture)

30. May 1st 2009 Latent HPV Infection - Reactivation vs Reinfection. HPV Specialist Symposium, Copenhagen, Denmark (Invited Lecture)

31. May 11th 2009 The Future of Papillomavirus Research (the viral life cycle), 25th International Papillomavirus Meeting, Malmo, Sweden (Plenary Lecture, Session Chair)

32. June 24th 2009 The Biology of Human Papillomavirus Infection an Disease, University of York (Invited Research Seminar)

33. October 2nd 2009 How Papillomaviruses cause Warts, Neoplasia and Cancers, British Association of Sexual Health and HIV, Royal Society of Medicine, London, UK (Invited Lecture)

34. October 8th 2009 Papillomaviruses - How they cause warts and why some types cause cancers, UCL Virology Research Day, Royal Free Campus, London (Invited Research Seminar)

35. October 13th 2009 Understanding HPV and HPV Vaccines, 16th International Meeting of the European Society of Gynaecological Oncology, Belgrade, Serbia (Invited Lecture)

36. November 6th 2009 Human Papillomaviruses; Past, Present and Future, North London Colposcopy Society, Royal Free Hospital, London (Invited Research Seminar)

37. November 10th 2009 Human Papillomavirus Infection an Disease, Sanofi Pateur MSD, Lyon, France (Invited Research Seminar)

38. November 17th 2009 Understanding the Biology of HPV-Associated Disease, Fritz Lipmann Institute, Jena, Germany (Invited Research Seminar)

39. December 3rd 2009 Papillomavirus Regulation and De-regulation during Neoplastic Progression, Division of Virology, University of Tubingen, Germany (Invited Research Seminar)

40. February 3rd 2010 The Molecular Basis of Papillomavirus Infection and Disease, University of Leeds. (Invited Research Seminar)

41. February 15th 2010 Regulation and De-Regulation of The Human Papillomavirus Life Cycle, Infection and Cancer Symposium, DKFZ, Heidelberg, Germany. (Plenary Lecture)

42. February 17th 2010 Updating Papillomavirus Molecular Biology and Pathogenesis, Eurogin training course, Monaco (Invited Lecture, Session Chair)

43. March 6th &amp;amp; 7th 2010 1) Current thinking on Papillomavirus Infection, Lesion Formation, Regression and Latency. 2) Regulation of the normal Papillomavirus Life Cycle and Why Things Sometimes go Wrong. Second Advanced Summer School in Africa on Molecular Mechanisms of Virus Infection and Propogation. Hermanus, South Africa, March 6 -14th 2010 (Invited Lectures, Session Chair)

44. May 6th 2010 The Molecular Basis of Papillomavirus Infection and Disease, University of Piemonte Orientale, Novara, Italy. (Invited Research Seminar)

45. March 12th 2010 The Link between Viruses and Cancer. 1st Nordic Gynecologic Meeting on HPV Vaccination, Copenhagen, Denmark. (Invited Lecture)

46. May 27th 2010 Understanding the Biology of Human Papillomavirus Infection and Disease. University College Hospital, Cardiff, UK. (Invited Research Seminar)

47. April 9th 2010 The Biology and Role of HPV in Genital Infection. Irish Colposcopy Training Course, Coombe Womens Hospital, Dublin, Ireland. (Invited Lecture)

48. May 19th 2010 Viral Epithelial Interactions in Cervical HPV Infection. Oslo University Hospital, Norway (Invited Lecture)

49. June 2nd 2010 Biomarker Combinations for the Diagnosis of Cervical Disease, Becton Dickinson, Raleigh, USA. (Invited Lecture)

50. June 9th 2010 The Papillomavirus Life Cycle; gaps in knowledge and the use of model systems. Roche, Palo Alto, USA. (Invited Lecture)

51. June 10th 2010 Biomarker Combinations for the Diagnosis of Cervical Disease, Ventana Diagnostics, Tucson, USA. (Invited Lecture)

52. July 3rd 2010 Natural History of HPV Infection from the Biological Perspective. IPV Clinical Training Course, Montreal, Canada. (Invited Lecture)

53. July 7th 2010 The Natural History of Papilomavirus Disease. IPV Conference, Montreal, Canada. (Plenary Lecture, Session Chair) 

54. July 26th 2010 HPV Pathogenesis. (two lectures). Principles of Sexually Transmitted Disease Course, Seattle, USA. (Invited Lecture)

55. July 27th 2010 Understanding the Biology of Human Papillomavirus Infection and Disease. Fred Hutchinson Cancer Research Centre, Seattle, USA. (Invited Research Seminar)

56. November 25/26th 2010 Molecular biology of human papillomavirus infection and cervical cancer; The papillomavirus life cycle; Papillomavirus life cycle organization and biomaker selection Regional Meeting on HPV, Izmir, Turkey. (Invited Lecture, Session Chair)

57. January 13th 2011 Papillomavirus Life Cycle Regulation in Infected Epithelium. ICGEB, Trieste, Italy. (Invited Research Seminar)

58. March 15th 2011 Regulation of the Papillomavirus Life Cycle in the Skin. Institute Pasteur, Paris, France. (Invited Research Seminar)

59. April 18th 2011 The Rational Selection of Biomarkers for HPV Diagnosis. Scottish HPV Investigators Meeting, Edinburgh, Scotland. (Invited Research Seminar)

60. June 28th 2011 Papillomavirus and Disease. Fortismere School Medical Society, East Finchley, London. (Invited Lecture)

61. July 4th, 5th, 6th 2011 Papillomaviruses, Therapy and Diagnostics. (four lectures) 14th World Congress of Cervical Pathology and Colposcopy, Rio be Janeiro, Brazil. (Invited Lectures, Session Chair)

62. September 13th 2011 How Papillomaviruses Cause Serious Human Disease. British Association of Sexual Health and HIV, Keele, UK. (Plenary Lecture)

63. November 9th 2011 HPV life-cycle regulation during productive infection, neoplasia and latency. Cancer Colloquia on HPV Therapeutics. St Andrews, Scotland. (Invited Research Seminar)

64. November 25th 2011 The Biology of HPV-Associated Disease. 2nd Colposcopy and Cervical Pathology Congress, Antalya, Turkey. (Invited Lecture, Session Chair)

65. February 7th 2012 The Life-Cycle of Mucosal and Cutaneous Papillomaviruses. Centre for Virus Research, Glasgow, UK. (Invited Research Seminar)

66. March 20th 2012 The Basis for Papillomavirus Latency. SPMSD Lyon, France. (Invited Lecture)

67. March 21th 2012 Alpha and Beta HPV types in latency, disease and cancers. CLARA Cancer Meeting, Lyon, France. (Invited Lecture)

68. April 20th 2012 HPV Disease Aetiology. 40th Annual Scientific Meeting. British Society for Colposcopy and Cervical Pathology, Newcastle, UK. (Invited Lecture)

69. July 7th 2012 The Biology of HPV Disease. Eurogin Conference on HPV-Associated Cancers. Prague, Czechoslovakia. (Invited Lecture)

70. September 24th 2012 HPV life-cycle regulation in the epithelium. Department of Medicine, Imperial College, London, UK. (Invited Research Seminar)

71. 19th October 2012 Beta and Alpha Papillomaviruses. 6th International Conference of HPV, Polyomavirus and UV Radiation in Skin Cancer. Berlin, Germany (Invited Lecture, Session Chair)

72. 26th October 2012 Understanding the Biology of Human Papillomavirus Infection and Disease. Viruses, Genes and Cancer Meeting. Venice, Italy (Plenary Lecture)

73. 15th November 2012 The HPV Life Cycle. NCRI Clinical Trials Meeting, Academy of Medical Sciences, London, UK. (Invited Lecture)

74. 30th November 2012 The Molecular Biology of HPV Infection. 28th International Papillomavirus Meeting, Clinical Workshop, San Juan, Puerto Rico, USA (Invited Lecture, Session Chair)

75. 25th January 2013 Papillomaviruses, Epithelial Differentiation and the Regulation of Productive Infection. ICGEB, Trieste, Italy. (Invited Research Seminar) Available on Itunes U. 

76. 22nd June 2013 Development of an LSIL Biomarker for use in Conjunction with HSIL Biomarkers for Diagnosis of Cervical Disease Severity. 10th Congress of Colposcopy and Cervical Pathophysiology, Krakow, Poland (Invited Lecture)

77. 20th September 2013 The Human Papillomavirus Life Cycle; Regulation and Deregulation. Danish Cancer Research Centre, Copenhagen, Denmark. (Invited Research Seminar)

78. 3rd November 2013 Current Understanding of HPV Disease. Eurogin Conference on HPV-Disease. Florence, Italy. (Invited Lecture)

79. 10th April 2014 Life Cycle Strategies, Epithelial Tropisms and Disease Outcome. 7th International Conference of HPV, Polyomavirus and UV Radiation in Skin Cancer. Novarello Village, Novara, Italy. (Invited Lecture, Session Chair) 

80. 28th May 2014 Use of Viral and Cellular Biomarker Combinations to Assess Disease Severity. 15th World Congress for Cervical Pathology and Colposcopy (IFCPC 2014). Queen Elizabeth 2nd Centre, London (Plenary Lecture)

81. 30th May 2014 1) The Papillomavirus Life Cycle, 2) The Role of Viral Biomarkers in the Detection of Premalignancies of Cervical Cancer, 3) HPV Latency, Molecular Mechanisms and Patterns of Gene Expression. IFCPC Molecular Markers Workshop, NIMR, London (Invited Lecture Series, Session Chair)

82. 2nd June 2014 HPV Diversity, Capsid Structure &amp;amp; Immune Recognition. SPMSD Advisory Board. Royal College of Physicians, St Andrews Place, Regent's Park, London NW1 4LE (Invited Lecture)

83. 3rd June 2014 HPV Life Cycle - An Overview. Abbott Molecular Symposium on Cervical Cancer Prevention and HPV - are we there yet? Midland Hotel, Peter St, Manchester (Invited Lecture)

84. 13th June 2014 Understanding the papillomavirus Life Cycle and Disease. Cancer and Development Graduate Research Symposium, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL Canada (Invited Research Seminar, Session Chair)

85. 23rd June Pathology Symposium Human Papillomavirus Protein Regulation &amp;amp; Function in the Epithelium. Annual Research Symposium, Li Ka Shing Centre, Cambridge Cancer Research UK. (Invited Research Seminar)

86. 24th June Reading Human Papillomavirus Life Cycle Regulation &amp;amp; Association with Cancer. School of Biological Sciences University of Reading. (Invited Research Seminar)

87. August 20, 2014. Viral Tropisms &amp;amp; the Site-Specific Development of HPV-Associated Neoplasias. 29th International Papillomavirus Conference &amp;amp; Clinical Workshop, Pre-Conference Clinical &amp;amp; Public Health Workshop, Washington State Convention Center (Invited Lecture)

88. August 24, 2014. The Natural History of HPV Infections Current Thinking. 29th International Papillomavirus Conference &amp;amp; Clinical Workshop, Main Conference, Washington State Convention Center (Invited Lecture, session chair)

89. 1st October 2014 The Role of Viral Biomarkers in the Detection of Premalignancies of Cervical Cancer. Erasmus Medical School, University of Rotterdam, The Netherlands. (Invited Research Seminar)

90. 6th November 2014 Pathogenesis of HPV-Related Neoplasia. European Anioscopy Meeting, Homerton Hospital, UK (Invited Lecture)

91. 20th &amp;amp; 21st November 2014 1) Biology and Life-Cycle of High and Low-Risk Human Papillomaviruses. 2) Biomarker Patterns in the Diagnosis of Cervical Neoplasia. ICGEB South American Workshop on HPV, University of Rosario, Rosario, Argentina. (Invited Research Seminar)

92. 4th February 2015 The Biology of HPV Infection at Different Epithelial Sites. Training Session, EUROGIN 2015 Congress on HPV Cancer, Sevilla, February 4-7, 2015 (Invited Lecture)

93. 6th February 2015 The Natural History of HPV Infections Current Thinking - Viral Gene Expression &amp;amp; Disease. Main Conference, EUROGIN 2015 Congress on HPV Cancer, Sevilla, February 4-7, 2015 (Invited Lecture, session chair)

94. 20th March 2015 The Natural History of HPV Infections. Current Thinking - Viral Gene Expression &amp;amp; Disease. German Society of Virology Meeting, Dusseldorf, Germany (Invited Lecture)

95. 17th April 2015 Molecular Markers in Pre-Invasive Disease. How can they help the Colposcopist? British Society for Colposcopy and Cervical Pathology Annual Meeting, Nottingham, UK. (Invited Research Seminar)

96. 9th Sept 2015 Papillomavirus Life Cycle Biology and Models of Disease. Huntingdon Life Sciences, Huntingdon, Cambridgeshire, UK. (Invited Research Seminar)

97. 17th September 2015 HPV Carcinogenesis: Step by Step. Clinical Workshop, 30th International Papillomavirus Conference &amp;amp; Clinical and Public Health Workshops, Lisbon, Portugal. (Invited Lecture)

98. 18th September 2015 Human Papillomavirus Molecular Biology &amp;amp; Pathogenesis. Main Conference 30th International Papillomavirus Conference &amp;amp; Clinical and Public Health Workshops (HPV 2015) (Invited Lecture)

99. 10th October 2015 The Biology of HPV Infection at the Cervix. Advances in HPV Diagnostics, Tokyo, Japan (Invited Lecture)

100. 15th October 2015 HPV Pathogenesis and the Basis of Disease. 2nd European Anioscopy Meeting, Homerton Hospital, London. (Invited Lecture)</gtr:impact><gtr:outcomeId>56dd7c2baf57b9.05106530</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL and Imperial College Lecture Course</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>00230F1E-13F3-41B6-8197-21143926FF1D</gtr:id><gtr:impact>student learnt about papillomaviruses

recruitment of PhD student</gtr:impact><gtr:outcomeId>rd65ZwNPWsV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HPV training sessions for Clinical Scientists</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B71A4055-5857-4626-A7E3-DE52FE70CA54</gtr:id><gtr:impact>Seminar presentation followed by workshop discussions and often clinical collaborative work to answer research questions.

Many requests for slides and information and possible follow-up work to answer research questions.</gtr:impact><gtr:outcomeId>54622fc3686510.38900165</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Students - LSHTM, Imperial, UCL, Cambridge</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8D608580-73E6-4192-B66F-0E3FE419A334</gtr:id><gtr:impact>Lecture

Recruitment of students wishing to do PhD-level research</gtr:impact><gtr:outcomeId>AD51F0AECD6</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits/Events During National Science week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>246B8F06-89B5-4A42-BFDB-7DF277173356</gtr:id><gtr:impact>Talks to school children at their schools. Workshop during science week at NIMR.

Generation of good links with the local community</gtr:impact><gtr:outcomeId>A710FFAB01B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Colposcopy course - UCL</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6AA376BE-A2CC-4013-9346-33BD31F248E6</gtr:id><gtr:impact>Education into papillomavirus biology

Collaboration with clinical scientists</gtr:impact><gtr:outcomeId>EEAEAA62D0B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>204354</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome-Research Training Fellowship</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>F509B806-6361-482C-92E0-BE66130B05FA</gtr:id><gtr:outcomeId>97FAD3EC9950</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>217209</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>gsk-Collaborative Research Grant-2008</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>9B343061-2954-4013-AA9E-69A424920EA6</gtr:id><gtr:outcomeId>58B9D54A3900</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University College London-Project</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>077534EC-E363-41C4-845C-766016454CFD</gtr:id><gtr:outcomeId>KwRvbCECcZX0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>93783</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>sanofi pasteu MSD-Research Project-2009</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Sanofi Pasteur MSD</gtr:fundingOrg><gtr:id>DEBF014B-AC47-4CF6-B722-BB885CADA432</gtr:id><gtr:outcomeId>E56C61CA5AA0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>sanofi pasteu MSD Research Project-2011</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Sanofi Pasteur MSD</gtr:fundingOrg><gtr:id>5B2EB269-F07A-411D-B25C-F5AA0EECE146</gtr:id><gtr:outcomeId>mVMb32RAgQ50</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17226</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>sanofi pasteu MSD Research Project 2011</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Sanofi Pasteur MSD</gtr:fundingOrg><gtr:id>091836FA-BE08-482C-9173-93E8B672BDA8</gtr:id><gtr:outcomeId>Sen2x2wRsEv0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>236718</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>gsk-Collaborative Research Grant-2007</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>7B484704-37D0-4461-89CF-81C60D8ACDE9</gtr:id><gtr:outcomeId>9D3F7DA3F760</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Use of the E4 Human Papilloma Virus (HPV) marker to screen for precancerous lesions of the cervix and E4-specific antibody that could be used in screening. Patent granted in Europe, Canada, US, Japan and Australia.</gtr:description><gtr:grantRef>MC_U117584278</gtr:grantRef><gtr:id>93DE8D93-0D09-4574-AB4D-748E2203004A</gtr:id><gtr:impact>collaborative research in place as a result and ongoing interest from diagnostic companies Roche, Becton Dickinson and DDL.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>F5E7AA6942B</gtr:outcomeId><gtr:patentId>US2003219726?</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>HPV identification</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI workshop</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>995D99CC-29E5-4F24-805E-EC5F39AD2AB3</gtr:id><gtr:impact>direction of research program influenced</gtr:impact><gtr:outcomeId>qdp6e6FYdd6</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Roche, SPMSD, Merck, GSK consultancy</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>CC5709B7-8B7B-4C55-92EF-CF4E1551D5CF</gtr:id><gtr:impact>Advice to many companies on the best use of diagnostics, and on the HPV vaccine and its implementation</gtr:impact><gtr:outcomeId>kdwEUmrmrt5</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cancer Research France</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>CE7C4F61-7A0B-4922-B3A3-4EF9BF356D4C</gtr:id><gtr:impact>Funding Review Board advisor</gtr:impact><gtr:outcomeId>R1ooUX8X6de</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Institute Scientific Review Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B78DF48D-8EB3-47AB-A6D7-4A87C8F434BF</gtr:id><gtr:impact>Influence on Virology Research at the Pasteur Institute, Paris; ICGEB, Trieste; Leibniz Institute for Age Research, Jenna</gtr:impact><gtr:outcomeId>41C3C92ADB2</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific Presentations to Clinical Audiences</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A6C854BE-1F9B-4B89-8C9E-7BF3F00B8CDC</gtr:id><gtr:impact>Major seminars to key societies involved in implementing new policies on cervical diagnostics.

e.g. 

1. 10th October 2015 The Biology of HPV Infection at the Cervix. Advances in HPV Diagnostics, Tokyo, Japan (Invited Lecture)

2. 17th April 2015 Molecular Markers in Pre-Invasive Disease. How can they help the Colposcopist? British Society for Colposcopy and Cervical Pathology Annual Meeting, Nottingham, UK.

3. 6th February 2015 The Natural History of HPV Infections Current Thinking - Viral Gene Expression &amp;amp; Disease. Main Conference, EUROGIN 2015 Congress on HPV Cancer, Sevilla, February 4-7, 2015</gtr:impact><gtr:outcomeId>56dd7f740e7f12.73873365</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NIHR evaluation of HPV testing</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>811DBAC4-0C67-404B-AC84-DE5B378AD983</gtr:id><gtr:impact>decision as to whether to use HPV testing more widely within the NIH</gtr:impact><gtr:outcomeId>C25F43D789A</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Cofounder of the Papillomavirus data base now in widespread use by researchers in the HPV field. Updated annually</gtr:description><gtr:id>F5182EE2-8703-4163-81C4-940DAC12B0FB</gtr:id><gtr:impact>Ease of analysis of all papillomavirus sequences and other data including reviews by members of the PV research community.</gtr:impact><gtr:outcomeId>5462336f6a38d6.46071087</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PAVE Papillomavirus Database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://pave.niaid.nih.gov</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Method for using the E4 biomarker as an aid to cervical diagnosis. This patent underlies the approx 500000 of research funding previously provided by GSK to our lab. This work is now the subject of a licence agreement with DDL in the Netherlands. Collaborative manuscripts published</gtr:description><gtr:id>0D375612-C7C6-4562-9058-828FA604145D</gtr:id><gtr:impact>Material transferred to Ventana Medical Systems Inc, May 2008 and CytoImmune Diagnostics GmbH, Aug 2009 for use in vaccine production/diagnostics. Currently being evaluated with a view to development as a commercial diagnostic. Is in final stage of being picked up as a diagnostic test by DDL, The Netherlands.</gtr:impact><gtr:outcomeId>DE977770CEA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Improvements in or relating to screening for Papilloma virus</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Advanced version with descriptive menu. Animations of all aspects of HPV biology produced in conjunction with Joe Brock at MRC-NIMR and distributed widely to research, education and health care workers to enhance understanding of disease mechanisms and vaccine utility.</gtr:description><gtr:id>3D6AE7C0-B7EC-4513-A636-CC3951813ABB</gtr:id><gtr:impact>Adding the animation to presentations has generally increased the status of the research group and its prominence worldwide.</gtr:impact><gtr:outcomeId>54623a1ff18d54.67527505</gtr:outcomeId><gtr:title>Scientific animations for public awareness</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D99E4B79-CCFD-4FF7-B01E-0961A0002E7D</gtr:id><gtr:title>Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9ff506d91f74efac692ee123c70ddab"><gtr:id>d9ff506d91f74efac692ee123c70ddab</gtr:id><gtr:otherNames>Sterlinko Grm H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>5461f179ca7e35.43263767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F856D50-9F40-40C2-85BD-8595FC81D8D0</gtr:id><gtr:title>Papillomavirus life cycle organization and biomarker selection.</gtr:title><gtr:parentPublicationTitle>Disease markers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0278-0240</gtr:issn><gtr:outcomeId>5461f17be07f38.47390473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64941E46-484B-421A-B929-422EF4A5E8E3</gtr:id><gtr:title>Characterization of skin lesions induced by skin-tropic a- and ?-papillomaviruses in a patient with epidermodysplasia verruciformis.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d41ca798f0a60932ceaf6f1d0e3637b4"><gtr:id>d41ca798f0a60932ceaf6f1d0e3637b4</gtr:id><gtr:otherNames>Borgogna C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>5461f1803952a5.26468611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7666000B-662A-4971-8A59-66F1453BDB34</gtr:id><gtr:title>Which HPV Type Caused that Lesion?</gtr:title><gtr:parentPublicationTitle>HPV Today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9295526adebed53ae12860ff30dcf4a"><gtr:id>e9295526adebed53ae12860ff30dcf4a</gtr:id><gtr:otherNames>Quint, W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>HTBFrfSNtPt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DE1AA70-5E5B-413A-8325-55086BB2393E</gtr:id><gtr:title>Latent papillomavirus infections and their regulation.</gtr:title><gtr:parentPublicationTitle>Current opinion in virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1879-6257</gtr:issn><gtr:outcomeId>pm_16203_23_23816390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>517005D0-BAF9-4B8E-9EDD-471E77C480A8</gtr:id><gtr:title>The human papillomavirus type 11 E1/\E4 protein is not essential for viral genome amplification.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fe56147345fee39e68e8e6ab813fbf"><gtr:id>03fe56147345fee39e68e8e6ab813fbf</gtr:id><gtr:otherNames>Fang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>5461f17b95ef44.14027110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD7C60BA-7038-4EF2-AD82-FA5CDFD586D5</gtr:id><gtr:title>Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7302809953bb0edcba63185d2fac5efc"><gtr:id>7302809953bb0edcba63185d2fac5efc</gtr:id><gtr:otherNames>Isaacson Wechsler E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_16203_23_22457518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D048C6AF-9253-4CB7-8524-C3D459BCBD1E</gtr:id><gtr:title>E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67ce09e20d856408a7b59f5c51db18c8"><gtr:id>67ce09e20d856408a7b59f5c51db18c8</gtr:id><gtr:otherNames>Griffin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16203_23_23226504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>622EA0BE-D33F-42E2-A583-AF9790364D5C</gtr:id><gtr:title>Investigating Diagnostic Problems of CIN1 and CIN2 Associated With High-risk HPV by Combining the Novel Molecular Biomarker PanHPVE4 With P16INK4a.</gtr:title><gtr:parentPublicationTitle>The American journal of surgical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/278cd646fcee38734c61b7aaf8aa220a"><gtr:id>278cd646fcee38734c61b7aaf8aa220a</gtr:id><gtr:otherNames>van Baars R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0147-5185</gtr:issn><gtr:outcomeId>56dd3a99efbad7.16659497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5526662-3CD7-4143-9C06-9606C99C3B62</gtr:id><gtr:title>G2/M cell cycle arrest in the life cycle of viruses.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30720519b1e78b3cc932e58c66cb023f"><gtr:id>30720519b1e78b3cc932e58c66cb023f</gtr:id><gtr:otherNames>Davy C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>2D647CE8D3A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A10110C-BF39-4887-B6E1-CDBFABAA314A</gtr:id><gtr:title>Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67ce09e20d856408a7b59f5c51db18c8"><gtr:id>67ce09e20d856408a7b59f5c51db18c8</gtr:id><gtr:otherNames>Griffin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>3DEF539F06B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F03573E7-D230-4AD6-9525-81C7B5B5C6BF</gtr:id><gtr:title>Phosphorylation of the human papillomavirus type 16 E1--E4 protein at T57 by ERK triggers a structural change that enhances keratin binding and protein stability.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f17c589739.32677099</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0BDF26B-6F6B-4494-9ECC-06AAB5FEC80B</gtr:id><gtr:title>Structural analysis reveals an amyloid form of the human papillomavirus type 16 E1--E4 protein and provides a molecular basis for its accumulation.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8bb1af3f013b69a2b59656152330523"><gtr:id>d8bb1af3f013b69a2b59656152330523</gtr:id><gtr:otherNames>McIntosh PB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f17c3673c6.39072640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C11B2F5A-280C-4228-AF44-FEF4640E53EE</gtr:id><gtr:title>Comprehensive control of human papillomavirus infections and related diseases.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d2551e32176161619011bd3f0ed27fc"><gtr:id>8d2551e32176161619011bd3f0ed27fc</gtr:id><gtr:otherNames>Bosch FX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5461f17fc34663.03039926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12C89FD2-3C56-4876-B148-446A0607370F</gtr:id><gtr:title>Deregulation of E-cadherin by human papillomavirus is not confined to high-risk, cancer-causing types.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b93c2dfaa452766bff78350d240d04e0"><gtr:id>b93c2dfaa452766bff78350d240d04e0</gtr:id><gtr:otherNames>Leong CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>5461f17e3405f2.85426344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76980383-1C46-41DC-BE34-67D9B0D27CF9</gtr:id><gtr:title>Detection of papillomavirus proteins and DNA in paraffin-embedded tissue sections.</gtr:title><gtr:parentPublicationTitle>Methods in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee312504c410eb94c5ce1bb62013bc22"><gtr:id>ee312504c410eb94c5ce1bb62013bc22</gtr:id><gtr:otherNames>Peh WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1543-1894</gtr:issn><gtr:outcomeId>216B3965E30</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49113451-8207-45DF-A1DE-A5A754C59AB4</gtr:id><gtr:title>Comprehensive control of human papillomavirus infections and related diseases.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d2551e32176161619011bd3f0ed27fc"><gtr:id>8d2551e32176161619011bd3f0ed27fc</gtr:id><gtr:otherNames>Bosch FX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5461f17f747346.74563065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>140856DC-DC12-476B-AE62-691662FCD0F6</gtr:id><gtr:title>Modulation of basal cell fate during productive and transforming HPV-16 infection is mediated by progressive E6-driven depletion of Notch.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a09fd884a23fdc979c7a1e13718f5e6"><gtr:id>9a09fd884a23fdc979c7a1e13718f5e6</gtr:id><gtr:otherNames>Kranjec C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5a2fd32d226854.83189820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F312548-231F-4032-B7C8-DBD55C4B114A</gtr:id><gtr:title>Detection of viral DNA and E4 protein in basal keratinocytes of experimental canine oral papillomavirus lesions.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79cf4476427475a654189c3a7a1e2408"><gtr:id>79cf4476427475a654189c3a7a1e2408</gtr:id><gtr:otherNames>Nicholls PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>5461f178d76012.65738713</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACD5AAEB-F80A-4587-A4A6-ACB5886D4593</gtr:id><gtr:title>a- and ?-papillomavirus infection in a young patient with an unclassified primary T-cell immunodeficiency and multiple mucosal and cutaneous lesions.</gtr:title><gtr:parentPublicationTitle>Journal of the American Academy of Dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4612e65a687f96394287a1d34002075b"><gtr:id>4612e65a687f96394287a1d34002075b</gtr:id><gtr:otherNames>Landini MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0190-9622</gtr:issn><gtr:outcomeId>5461f1801690a9.70960501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>560F47D4-1337-4870-98F6-267737F4AAFE</gtr:id><gtr:title>Human papillomavirus type 16 E1circumflexE4 contributes to multiple facets of the papillomavirus life cycle.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b962419f2521e51888926f20efde3ac"><gtr:id>7b962419f2521e51888926f20efde3ac</gtr:id><gtr:otherNames>Nakahara T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f17aa6d7a5.63233039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0D294DF-9E40-496E-A651-78ABD73A8745</gtr:id><gtr:title>HPV16 E1--E4 protein is phosphorylated by Cdk2/cyclin A and relocalizes this complex to the cytoplasm.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfaf51c1d2f5e917522a50d3482cec87"><gtr:id>dfaf51c1d2f5e917522a50d3482cec87</gtr:id><gtr:otherNames>Davy CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>5461f17b42b955.02568683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2631428A-1671-40B2-8E42-B858960F1D41</gtr:id><gtr:title>Synthesis of viral DNA and late capsid protein L1 in parabasal spinous cell layers of naturally occurring benign warts infected with human papillomavirus type 1.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac3b26beb8880a14309964e1cfed2b1a"><gtr:id>ac3b26beb8880a14309964e1cfed2b1a</gtr:id><gtr:otherNames>Egawa K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2000-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>5461f1788a80a6.92693550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FF83C18-5FA6-4370-80F8-19AA5E3D450A</gtr:id><gtr:title>The papillomavirus life cycle.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn><gtr:outcomeId>5461f17a5f2c17.93478256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EE03AC4-8D9E-4342-9F3C-9FB440D674E3</gtr:id><gtr:title>E1 empty set E4 protein of human papillomavirus type 16 associates with mitochondria.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/174b948f73bede6923dfbe44e3dc5003"><gtr:id>174b948f73bede6923dfbe44e3dc5003</gtr:id><gtr:otherNames>Raj K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f17a2aaa24.92248653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDDBF16B-4F87-44E3-BB4F-C6F001A181BE</gtr:id><gtr:title>Comprehensive control of human papillomavirus infections and related diseases.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d2551e32176161619011bd3f0ed27fc"><gtr:id>8d2551e32176161619011bd3f0ed27fc</gtr:id><gtr:otherNames>Bosch FX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5461f17f448141.26935397</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C9C6B1C-9CFF-49A2-969C-81C9BA8ABD4D</gtr:id><gtr:title>Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4e655eedfd66c45f05a170c80f4a98d"><gtr:id>e4e655eedfd66c45f05a170c80f4a98d</gtr:id><gtr:otherNames>Nicolaides L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>5461f17e89b344.37628394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82CDE1D0-83D5-4D7F-BE6E-F48CE1F16E89</gtr:id><gtr:title>Inhibition of HPV-16 E7 oncogenic activity by HPV-16 E2.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5153cf54c50f4f409fce9d7c85fae5fa"><gtr:id>5153cf54c50f4f409fce9d7c85fae5fa</gtr:id><gtr:otherNames>Gammoh N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5461f17c7ddd38.07435145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A13B9DF8-FED5-4D74-B199-99A9C967C4FB</gtr:id><gtr:title>The E4 protein; structure, function and patterns of expression.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>pm_16203_23_24016539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFF2D754-2FE8-4987-9BDD-93DAC2C06B9D</gtr:id><gtr:title>Role of calpain in the formation of human papillomavirus type 16 E1^E4 amyloid fibers and reorganization of the keratin network.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51bf8d095cd01ce4859824fd332cce8c"><gtr:id>51bf8d095cd01ce4859824fd332cce8c</gtr:id><gtr:otherNames>Khan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f17ee2d6e7.79767709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>025C0FB3-7F70-4A01-AC5E-F9FE2CDC0254</gtr:id><gtr:title>Quantitative measurement of human papillomavirus type 16 e5 oncoprotein levels in epithelial cell lines by mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39c8c303288c8af95b5d1b4cd9ce5f44"><gtr:id>39c8c303288c8af95b5d1b4cd9ce5f44</gtr:id><gtr:otherNames>Sahab Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_16203_23_22740411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>707070FC-2A75-4111-A881-D92F5CE0EFCB</gtr:id><gtr:title>Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25389bf512d2e8d62b76aa21e3f84902"><gtr:id>25389bf512d2e8d62b76aa21e3f84902</gtr:id><gtr:otherNames>Matthews K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f1795d89b3.36060330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73F6715D-7B82-4848-8F68-50F1478215D2</gtr:id><gtr:title>Inhibition of E6-induced Degradation of its Cellular Substrates by Novel Blocking Peptides</gtr:title><gtr:parentPublicationTitle>Journal of Molecular Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9ff506d91f74efac692ee123c70ddab"><gtr:id>d9ff506d91f74efac692ee123c70ddab</gtr:id><gtr:otherNames>Sterlinko Grm H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>5a35184489e261.91043629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>542934EA-5E9F-4A52-97B7-FB5E4C2F5D40</gtr:id><gtr:title>Improved detection reveals active ?-papillomavirus infection in skin lesions from kidney transplant recipients.</gtr:title><gtr:parentPublicationTitle>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d41ca798f0a60932ceaf6f1d0e3637b4"><gtr:id>d41ca798f0a60932ceaf6f1d0e3637b4</gtr:id><gtr:otherNames>Borgogna C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0893-3952</gtr:issn><gtr:outcomeId>5461f17fe54a22.51961077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3345E556-9DF9-47FA-8011-307A82D49475</gtr:id><gtr:title>Molecular basis for advances in cervical screening.</gtr:title><gtr:parentPublicationTitle>Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1084-8592</gtr:issn><gtr:outcomeId>5461f17aca0a00.60505091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1A15931-8D30-465C-9CFD-23A934497A4F</gtr:id><gtr:title>Immunosuppression facilitates the reactivation of latent papillomavirus infections.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bd3c5d25381fa918c81bbe76a4b901c"><gtr:id>0bd3c5d25381fa918c81bbe76a4b901c</gtr:id><gtr:otherNames>Maglennon GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_16203_23_24173230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E06FA4A-E8E8-474D-B891-4CD092184873</gtr:id><gtr:title>Analysis of host-parasite incongruence in papillomavirus evolution using importance sampling.</gtr:title><gtr:parentPublicationTitle>Molecular biology and evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a3f709f315460299c6b9cf9f269bf54"><gtr:id>8a3f709f315460299c6b9cf9f269bf54</gtr:id><gtr:otherNames>Shah SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0737-4038</gtr:issn><gtr:outcomeId>5461f17d1f46c3.14912481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84DEA082-E520-44C8-87B4-B193732293B6</gtr:id><gtr:title>Functional analysis of the human papillomavirus type 16 E1=E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f179a923b4.01844113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DCC9F32-EE12-43FC-A9D7-AB0B37F82698</gtr:id><gtr:title>One virus, one lesion--individual components of CIN lesions contain a specific HPV type.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d944d70b02ca74909ed9eab86c38b1"><gtr:id>b6d944d70b02ca74909ed9eab86c38b1</gtr:id><gtr:otherNames>Quint W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5461f17f1e28e5.42474043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42C630C2-3B4D-4DF9-B02A-15DFAAC99FD0</gtr:id><gtr:title>The biology and life-cycle of human papillomaviruses.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_16203_23_23199966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3B1834E-B481-479A-8275-CB3C441D4668</gtr:id><gtr:title>Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b93c2dfaa452766bff78350d240d04e0"><gtr:id>b93c2dfaa452766bff78350d240d04e0</gtr:id><gtr:otherNames>Leong CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>5461f17ca29b71.13605751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79FEC9D5-14BA-4B6B-AEB0-E4D8C28CED4F</gtr:id><gtr:title>The viral E4 protein is required for the completion of the cottontail rabbit papillomavirus productive cycle in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee312504c410eb94c5ce1bb62013bc22"><gtr:id>ee312504c410eb94c5ce1bb62013bc22</gtr:id><gtr:otherNames>Peh WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f17a0495f7.97990110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51A67140-A44B-4A48-8CCC-41E2A6950F51</gtr:id><gtr:title>Expression of betapapillomavirus oncogenes increases the number of keratinocytes with stem cell-like properties.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/111413b11368ddda8360f6fd563b84d2"><gtr:id>111413b11368ddda8360f6fd563b84d2</gtr:id><gtr:otherNames>Hufbauer M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_16203_23_24006432</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D099D4AB-DE61-46A3-A046-4F4926E93A50</gtr:id><gtr:title>ONCOGENIC HUMAN PAPILLOMAVIRUSES: High-Risk Human Papillomaviruses: Towards a Better Understanding of the Mechanisms of Viral Transformation, Latency and Immune-Escape.</gtr:title><gtr:parentPublicationTitle>The open virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c325a467a9e040e95f3c96b4ca02b72"><gtr:id>1c325a467a9e040e95f3c96b4ca02b72</gtr:id><gtr:otherNames>Cid Arregui A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1874-3579</gtr:issn><gtr:outcomeId>pm_16203_23_23346264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC9C538D-2042-4B18-81FF-3FFD25D36F35</gtr:id><gtr:title>Life cycle heterogeneity in animal models of human papillomavirus-associated disease.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee312504c410eb94c5ce1bb62013bc22"><gtr:id>ee312504c410eb94c5ce1bb62013bc22</gtr:id><gtr:otherNames>Peh WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f17936fc90.56513231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36C5EF56-B8E3-467E-AD03-7BAA3863E13D</gtr:id><gtr:title>Etiological role of human papillomavirus infection for inverted papilloma of the bladder.</gtr:title><gtr:parentPublicationTitle>Journal of medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43d9d9642bd8e1e24175aeba1794f45f"><gtr:id>43d9d9642bd8e1e24175aeba1794f45f</gtr:id><gtr:otherNames>Shigehara K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0146-6615</gtr:issn><gtr:outcomeId>5461f17e588798.90325287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90E13915-38C4-47FA-9B4E-4448505DE14F</gtr:id><gtr:title>The biology of papillomavirus latency.</gtr:title><gtr:parentPublicationTitle>The open virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bd3c5d25381fa918c81bbe76a4b901c"><gtr:id>0bd3c5d25381fa918c81bbe76a4b901c</gtr:id><gtr:otherNames>Maglennon GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1874-3579</gtr:issn><gtr:outcomeId>pm_16203_23_23341854</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD88A74C-09EE-4A38-B356-B62BBE12279F</gtr:id><gtr:title>Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfaf51c1d2f5e917522a50d3482cec87"><gtr:id>dfaf51c1d2f5e917522a50d3482cec87</gtr:id><gtr:otherNames>Davy CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f17a832162.62769073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE013243-016B-4A0E-B2B3-760F272D083B</gtr:id><gtr:title>Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bd3c5d25381fa918c81bbe76a4b901c"><gtr:id>0bd3c5d25381fa918c81bbe76a4b901c</gtr:id><gtr:otherNames>Maglennon GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>01AB6B5A_101AB6B5A_1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2821EBA4-8B12-4733-BF6C-70E186389DE3</gtr:id><gtr:title>A novel interaction between the human papillomavirus type 16 E2 and E1--E4 proteins leads to stabilization of E2.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30720519b1e78b3cc932e58c66cb023f"><gtr:id>30720519b1e78b3cc932e58c66cb023f</gtr:id><gtr:otherNames>Davy C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>1AF4E057263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04F37AAD-C774-4717-AC50-34E3613FFE54</gtr:id><gtr:title>The E1E4 protein of human papillomavirus type 16 associates with a putative RNA helicase through sequences in its C terminus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2000-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f178b34e85.89900080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DB124A8-AC45-45EE-A8FB-F21B9911E64E</gtr:id><gtr:title>Human papillomavirus type 8 interferes with a novel C/EBP?-mediated mechanism of keratinocyte CCL20 chemokine expression and Langerhans cell migration.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ffe6ec5320b2749a44ab0757cdf89d7"><gtr:id>6ffe6ec5320b2749a44ab0757cdf89d7</gtr:id><gtr:otherNames>Sperling T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_16203_23_22911498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FA05852-D811-4BE2-BFF2-6C175F0DB50A</gtr:id><gtr:title>European Medicines Agency Report (2010) Exploratory Study Report for new technologies and biomarkers on HPV-16/18 associated CIN2+cases at final analysis of Study 580299/008 (HPV-008) (Development Phase III) (26 April 2010) IND Number: BB-IND 7920</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0335f5a79ab161dcd7bf2a9b3d4e0930"><gtr:id>0335f5a79ab161dcd7bf2a9b3d4e0930</gtr:id><gtr:otherNames>Colau,B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>bUZ7kywzPhQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBC2C85A-F9A7-4A4C-A692-A8EFE4DEB4A4</gtr:id><gtr:title>Characterization of beta papillomavirus E4 expression in tumours from Epidermodysplasia Verruciformis patients and in experimental models.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d41ca798f0a60932ceaf6f1d0e3637b4"><gtr:id>d41ca798f0a60932ceaf6f1d0e3637b4</gtr:id><gtr:otherNames>Borgogna C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>pm_16203_23_22217391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>303EA443-68F1-4A4D-9D2C-A60E36947889</gtr:id><gtr:title>Comprehensive control of human papillomavirus infections and related diseases.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d2551e32176161619011bd3f0ed27fc"><gtr:id>8d2551e32176161619011bd3f0ed27fc</gtr:id><gtr:otherNames>Bosch FX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5461f17f9d1d28.25772647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80130D2B-06F6-4CA4-9C52-17B3582226DF</gtr:id><gtr:title>E1--E4-mediated keratin phosphorylation and ubiquitylation: a mechanism for keratin depletion in HPV16-infected epithelium.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8bb1af3f013b69a2b59656152330523"><gtr:id>d8bb1af3f013b69a2b59656152330523</gtr:id><gtr:otherNames>McIntosh PB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>5461f17d57ef98.32864422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB131C9A-6887-42DB-BEF8-4FA161E8934B</gtr:id><gtr:title>HPV infection, the nature of the infected cell, and the outcome of cervical disease.</gtr:title><gtr:parentPublicationTitle>HPV Today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/720a6042ff9bb078f1ff568dd5fc7d25"><gtr:id>720a6042ff9bb078f1ff568dd5fc7d25</gtr:id><gtr:otherNames>Doorbar,J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>JmXwFc18iLA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BB9C990-5905-45BD-A6D7-E4505A15540D</gtr:id><gtr:title>HPV-18 E2^E4 chimera: 2 new spliced transcripts and proteins induced by keratinocyte differentiation.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106c063dfa5fa46bd35ebd7828c2d3a9"><gtr:id>106c063dfa5fa46bd35ebd7828c2d3a9</gtr:id><gtr:otherNames>Tan CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>pm_16203_23_22541938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD23DE37-0037-48E6-83BE-B28DED9A4484</gtr:id><gtr:title>Intrabody strategies for the treatment of human papillomavirus-associated disease.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>5461f17bbc9289.25008843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B58C688-C1B0-425D-B665-6CBB387A9563</gtr:id><gtr:title>Molecular biology of human papillomavirus infection and cervical cancer.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>5461f17b6836f9.40480523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DDEB9FE-F6E4-4668-9A0F-CA54BEAB8B51</gtr:id><gtr:title>Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM.</gtr:title><gtr:parentPublicationTitle>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67ce09e20d856408a7b59f5c51db18c8"><gtr:id>67ce09e20d856408a7b59f5c51db18c8</gtr:id><gtr:otherNames>Griffin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0893-3952</gtr:issn><gtr:outcomeId>56dd3a9a844277.44920900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DFBA759-F537-4B86-A9EC-A88374C3BE98</gtr:id><gtr:title>Expression of papillomavirus L1 proteins regulated by authentic gene codon usage is favoured in G2/M-like cells in differentiating keratinocytes.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/494ba6196af3cd99ac66b5a0659118db"><gtr:id>494ba6196af3cd99ac66b5a0659118db</gtr:id><gtr:otherNames>Ding J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>5461f17cebe3e5.85548082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B085B666-DD82-4F35-B008-EDF247230D23</gtr:id><gtr:title>Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d3a420bd1c44bd62726fa717f9243e9"><gtr:id>9d3a420bd1c44bd62726fa717f9243e9</gtr:id><gtr:otherNames>Middleton K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f17982f8f9.98455477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F12FD06D-C990-4891-9E57-1D6B4486732E</gtr:id><gtr:title>Identification of a G(2) arrest domain in the E1 wedge E4 protein of human papillomavirus type 16.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfaf51c1d2f5e917522a50d3482cec87"><gtr:id>dfaf51c1d2f5e917522a50d3482cec87</gtr:id><gtr:otherNames>Davy CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5461f1790ed8e7.98165917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54128D1F-3EBC-431D-98FD-176F6C781799</gtr:id><gtr:title>Position paper--HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians.</gtr:title><gtr:parentPublicationTitle>European journal of pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f29905ef4165384ef191aeb9066fa190"><gtr:id>f29905ef4165384ef191aeb9066fa190</gtr:id><gtr:otherNames>Ramet J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0340-6199</gtr:issn><gtr:outcomeId>5461f17d7a5329.86194767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A6633C3-8971-4D71-AA62-81D99D31FEC0</gtr:id><gtr:title>Biology of papillomavirus replication in infected epithelium</gtr:title><gtr:parentPublicationTitle>Future Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>357E1863866</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U117584278</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>